Aptuit Names CSO

Dr. Jan-Olav Henck has been named chief scientific officer at Aptuit. Dr. Henck will report to Stuart E. Needleman, president of Aptuit Scientific Operations. Aptuit’s chief executive officer, Tim Tyson, commented that the establishment of the CSO role reflects the company’s commitment to provide scientific expertise and strongly supports Aptuit’s focus to engineer a better drug development process through scientific excellence.

Mr. Tyson explained, “Science is at the forefront of our mission, and we firmly believe that having a CSO in place will enhance our overall service offering. The CSO will coordinate the scientific capabilities and efforts of our company, managing developments as well as partnerships for pharmaceutical research and development.

In 1999, Dr. Henck joined Bayer HealthCare, where he focused on solid-state chemistry of drugs and its impact on pharmaceutical formulations. In 2005, he was appointed research director in Analytical Research at SSCI. He later became a senior director at SSCI, leading the chemistry group with a primary focus on polymorphism studies, cocrystal and salt screening, amorphous screens and computational studies of drug substances. Most recently, Dr. Henck was site director for what had become Aptuit’s SSCI Division.

Mr. Needleman noted that Dr. Henck has “worked tirelessly to further expand the scientific knowledge of peers and Aptuit clients.” He said, “Aptuit could not ask for a more qualified, accomplished and dedicated scientist than Jan-Olav, whose talents and background make him the ideal chief scientific officer at our company.”